- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- LY3526318, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 35
- States / cities
- Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 28 more
Clinical trials in New Haven, Connecticut
This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in New Haven
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Cystic Fibrosis
- Interventions
- Standard Dose YPT-01, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
- Interventions
- IM JZP-458, IV JZP-458
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
- Conditions
- Acute Myocardial Infarction
- Interventions
- Pexelizumab, Placebo infusion
- Drug
- Lead sponsor
- Procter and Gamble
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,745 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 180
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 142 more
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 3 Months to 4 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- Ritlecitinib 50 mg, Ritlecitinib 200 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Chronic Low-back Pain
- Interventions
- LY3556050, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 27 more
- Conditions
- Osteoarthritis
- Interventions
- LY3556050, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 32 more
- Conditions
- Prostatic Neoplasms
- Interventions
- PF-06755992, PF-06755990, TDS-IM Electroporation Device, Tremelimumab, PF-06801591, PF-06753512
- Biological · Device
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Bethesda, Maryland + 10 more
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- LY3556050, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 35
- States / cities
- Chandler, Arizona • Glendale, Arizona • Tempe, Arizona + 28 more
- Conditions
- Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
- Interventions
- MEK162, MEK inhibitor; oral, Physician's choice chemotherapy
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 77
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Interventions
- Absorb BVS, XIENCE
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more